Quick Answer
BIOCRYST PHARMACEUTICALS INC reported R&D Expense of $166.13 million for fiscal year 2025.
BIOCRYST PHARMACEUTICALS INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $166.13M | -4.9% |
| 2024 | $174.64M | -19.4% |
| 2023 | $216.57M | -14.5% |
| 2022 | $253.30M | +21.3% |
| 2021 | $208.81M | +69.8% |
| 2020 | $122.96M | +14.8% |
| 2019 | $107.07M | +26.1% |
| 2018 | $84.89M | +26.8% |
| 2017 | $66.96M | +9.8% |
| 2016 | $61.01M | -16.1% |
| 2015 | $72.76M | +40.5% |
| 2014 | $51.80M | +23.5% |
| 2013 | $41.94M | -14.7% |
| 2012 | $49.16M | -14.1% |
| 2011 | $57.25M | -31.8% |
| 2010 | $83.90M | +13.9% |
| 2009 | $73.66M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $44.60M | +8.6% | +2.8% |
| June 30, 2025 | $43.39M | +15.3% | +16.4% |
| March 31, 2025 | $37.27M | -19.8% | -9.3% |
| September 30, 2024 | $41.08M | -12.4% | +9.2% |
| June 30, 2024 | $37.62M | -26.6% | -19.1% |
| March 31, 2024 | $46.49M | -3.9% | -0.8% |
| September 30, 2023 | $46.88M | -11.1% | -8.5% |
| June 30, 2023 | $51.25M | -17.3% | +5.9% |
- BIOCRYST PHARMACEUTICALS INC showed a decrease of -4.9% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, BIOCRYST PHARMACEUTICALS INC’s r&d expense has grown by 125.5% (from $73.66 million to $166.13 million).
- The most recent figure is from BIOCRYST PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: